How to Apply to Alnylam Pharmaceuticals

9 min read Last updated April 20, 2026 87 open positions
Blake Crosley
Blake Crosley Researched using publicly available information, hiring data, and ATS analysis.

Key Takeaways

  • Alnylam invented commercialized RNAi therapeutics and is the platform leader — RNAi, oligonucleotide chemistry, and GalNAc-conjugate experience are the highest-leverage resume signals.
  • ATS is Eightfold (jobs.alnylam.com), which parses skills aggressively and cross-references your LinkedIn — keep both pristine and aligned.
  • HELIOS-B Phase 3 readout (mid-2024) for Amvuttra in ATTR cardiomyopathy is the defining commercial inflection — cardiology, cardiovascular medical affairs, market access, and field reimbursement hiring is at its peak.
  • Cambridge MA HQ with hybrid (typically 3 days on-site) for most R&D, clinical, and commercial roles; Norton MA manufacturing is fully on-site; some commercial field roles are remote-eligible.
  • Scientific rigor extends to non-bench interviews — be ready to discuss platform mechanism even for regulatory, commercial, or G&A roles.
  • Compensation is competitive with the Cambridge cluster (Vertex, Moderna, Biogen) — RSU-heavy, with significant equity upside if the post-HELIOS-B commercial ramp executes.
  • Honest risk: single-platform concentration on RNAi creates more correlated upside-and-downside than diversified large pharma, and biotech sector volatility (Nasdaq Biotech Index has had 30%+ drawdowns) directly affects RSU value.
  • Interview loops run 6-10 weeks for individual contributors, 3-4 months for senior director and VP roles — plan accordingly and don't ghost the recruiter mid-process.
  • The company is mission-driven about rare-disease patients in a way that is not performative — interviewers can tell within minutes whether candidates share that orientation.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (Nasdaq: ALNY) is the worldwide leader in RNA interference (RNAi) therapeutics, a medicine class it pioneered and commercialized after most of the pharmaceutical industry abandoned the field in the late 2000s. The company was founded in 2002 in Cambridge, Massachusetts as a spinoff from foundational RNAi research conducted at MIT, the Whitehead Institute, and Germany's Max Planck Institute, building directly on the Nobel Prize-winning discovery of RNA interference by Andrew Fire and Craig Mello (Nobel Prize in Physiology or Medicine, 2006). MIT Institute Professor Phillip Sharp, himself a Nobel laureate (1993) and a co-discoverer of RNA splicing, was a scientific co-founder and continues to serve as chair of Alnylam's scientific advisory board, anchoring the company's deep academic credibility. Alnylam was led for two decades by founding CEO John Maraganore, who shepherded the company from a $17 million seed-stage startup through the platform's near-collapse around 2010-2014 (when Big Pharma partners walked away) to the historic 2018 FDA approval of Onpattro (patisiran), the world's first-ever RNAi-based therapeutic, for hereditary transthyretin-mediated (hATTR) amyloidosis. Yvonne Greenstreet, MBChB, MBA, a former Pfizer executive who joined as COO in 2016, succeeded Maraganore as CEO in January 2022 and now leads the company through its commercial-stage transition. The marketed portfolio includes Onpattro and Amvuttra (vutrisiran) for ATTR amyloidosis, Givlaari (givosiran) for acute hepatic porphyria, Oxlumo (lumasiran) for primary hyperoxaluria type 1, and Leqvio (inclisiran) for hypercholesterolemia (licensed to and commercialized by Novartis). The pipeline includes zilebesiran for hypertension (partnered with Roche), nucresiran (next-generation ATTR), and earlier-stage CNS programs targeting Alzheimer's, Huntington's, and Parkinson's diseases. The HELIOS-B Phase 3 readout in mid-2024, demonstrating Amvuttra's significant cardiovascular benefit in ATTR cardiomyopathy, was the largest commercial inflection in Alnylam's history, opening a multibillion-dollar market against Pfizer's tafamidis and BridgeBio's acoramidis. Alnylam is headquartered in Cambridge's Kendall Square biotech cluster with manufacturing in Norton, Massachusetts and approximately 2,000 employees as of 2025.

Application Process

  1. 1
    Navigate to alnylam

    Navigate to alnylam.com/careers, which redirects to the Eightfold-powered careers portal at jobs.alnylam.com/careers. Eightfold is an AI-driven ATS used by many mid-to-large biotech and tech companies, and it relies heavily on resume parsing plus skills inference, so a clean, ATS-friendly resume matters more here than at companies running older Workday or Taleo stacks.

  2. 2
    Filter open roles by function (Research, Clinical, Regulatory, Commercial, Manuf

    Filter open roles by function (Research, Clinical, Regulatory, Commercial, Manufacturing, G&A), location (Cambridge MA HQ, Norton MA manufacturing, Maidenhead UK, Zug Switzerland, Tokyo, or Remote-eligible), and seniority. Most R&D and clinical roles are Cambridge-based hybrid (typically 3 days on-site); manufacturing is fully on-site in Norton.

  3. 3
    Create a candidate profile and either upload a resume or import from LinkedIn

    Create a candidate profile and either upload a resume or import from LinkedIn. Eightfold will auto-extract experience, skills, and education and suggest matching roles via its 'Talent Intelligence' engine — keep your LinkedIn current because the platform cross-references it.

  4. 4
    Submit a tailored resume (use the same job title language Alnylam uses in the JD

    Submit a tailored resume (use the same job title language Alnylam uses in the JD) and a short cover letter or 'Why Alnylam' note. Cover letters are not strictly required but they materially help for R&D, clinical, and commercial roles where motivation and platform fit are evaluated.

  5. 5
    Initial recruiter screen (30 minutes, phone or Teams) within 1-3 weeks of applic

    Initial recruiter screen (30 minutes, phone or Teams) within 1-3 weeks of application for actively prioritized roles. Recruiter will confirm work authorization (Alnylam sponsors H-1B and TN for hard-to-fill scientific roles but is more selective for commercial/G&A), compensation expectations, and on-site flexibility.

  6. 6
    Hiring manager interview (45-60 minutes, virtual), followed by a panel loop of 4

    Hiring manager interview (45-60 minutes, virtual), followed by a panel loop of 4-6 interviews including peer scientists, cross-functional partners (clinical, regulatory, CMC, or commercial depending on role), and a senior leader. Scientific and clinical roles typically include a 30-45 minute presentation of past work plus targeted technical Q&A.

  7. 7
    Final-round interviews are increasingly conducted on-site at the Cambridge campu

    Final-round interviews are increasingly conducted on-site at the Cambridge campus (200 Sidney Street and 675 West Kendall) for senior roles. Reference checks, background check, and offer typically follow within 1-2 weeks. End-to-end timeline averages 6-10 weeks; senior director and VP roles often run 3-4 months.

Resume Tips for Alnylam Pharmaceuticals

recommended

Lead with RNAi, oligonucleotide chemistry, or GalNAc-conjugate experience if you

Lead with RNAi, oligonucleotide chemistry, or GalNAc-conjugate experience if you have it — these are Alnylam's core platform technologies and recruiters and hiring managers screen aggressively for them. If you don't have direct RNAi experience, emphasize adjacent modalities (ASOs, mRNA, gene therapy, peptide therapeutics) and explicitly call out the transferable skills.

recommended

Quantify clinical or regulatory contributions: 'authored Module 2

Quantify clinical or regulatory contributions: 'authored Module 2.7 for BLA submission supporting 2023 FDA approval' lands far better than 'contributed to regulatory submissions.' Alnylam's regulatory and clinical teams have shipped four FDA approvals and they read resumes through that lens.

recommended

For commercial, medical affairs, and market access roles, name-drop relevant the

For commercial, medical affairs, and market access roles, name-drop relevant therapeutic areas: rare disease (ATTR amyloidosis, porphyria, hyperoxaluria), cardiology (the post-HELIOS-B build-out is hiring aggressively in cardiovascular medical affairs and field reimbursement), and orphan drug launches. Experience at Vertex, Sanofi Genzyme, Sarepta, Ultragenyx, BioMarin, or Ionis transfers extremely well.

recommended

Highlight FDA, EMA, PMDA, and Health Canada submission experience explicitly wit

Highlight FDA, EMA, PMDA, and Health Canada submission experience explicitly with submission types (IND, NDA, BLA, MAA, J-NDA, PIP, sNDA) and approval years. Global regulatory experience is highly valued because Alnylam launches products in 30+ countries through its own commercial infrastructure rather than fully outsourcing ex-US.

recommended

Use ATS-friendly formatting: single-column layout, standard section headers (Exp

Use ATS-friendly formatting: single-column layout, standard section headers (Experience, Education, Skills, Publications), no text in graphics or tables, .docx or PDF, 11-12pt body. Eightfold's parser is good but not perfect, and roughly 30% of candidates self-disqualify with parsing errors that hide their best experience.

recommended

Include publications, patents, and posters separately for scientific roles — eve

Include publications, patents, and posters separately for scientific roles — even one Nature, Cell, NEJM, or top-tier journal author credit dramatically increases callback rates for senior R&D positions. List Google Scholar or ORCID URL in the header.

recommended

Translate academic or postdoc work into industry-relevant terms

Translate academic or postdoc work into industry-relevant terms. 'Optimized siRNA stability via 2'-O-methyl modifications and tested in murine HeLa xenografts' is good; reframing as 'designed and screened chemically modified siRNA leads against [target class] using in vivo PK/PD models, supporting candidate nomination criteria' is better and signals industry maturity.

recommended

Soft-signal cultural fit: 'patient-focused,' 'cross-functional team leadership,'

Soft-signal cultural fit: 'patient-focused,' 'cross-functional team leadership,' and 'mission-driven' phrasing matters because Alnylam's interview loops explicitly probe values alignment, especially around the rare-disease patient community Alnylam has built deep relationships with.

Interview Culture

Alnylam's interview process is widely described by candidates as scientifically rigorous, collegial, and unusually mission-focused even by biotech standards.

The company's near-death experience between 2010 and 2014, when most pharma partners abandoned RNAi and Alnylam survived by sheer scientific conviction, has shaped a culture that takes platform belief and intellectual honesty seriously, and that worldview surfaces in every interview loop. Expect deep technical questions even in non-bench roles: a regulatory affairs candidate may be asked to explain GalNAc-conjugate liver targeting, and a commercial candidate may be asked to articulate why siRNA durability matters for patient adherence and payer messaging. Interview loops are panel-style with four to six interviewers including peers, cross-functional partners, and a senior leader; scientific roles always include a chalk-talk or slide presentation, typically thirty to forty-five minutes followed by aggressive but respectful technical Q&A. The company is in a genuine commercial inflection moment post-HELIOS-B, and you will feel that energy in the conversations — interviewers ask forward-looking questions about how candidates will help scale a launch organization that historically has been smaller and more research-driven, and they reward concrete, opinionated answers over generic platitudes. The Cambridge biotech cluster culture pervades: many interviewers are former Sanofi Genzyme, Vertex, Biogen, Moderna, Sarepta, or Ionis veterans, and there is an implicit expectation that candidates know the local ecosystem, have a perspective on competitive dynamics with Pfizer and BridgeBio in ATTR, and can speak to where RNAi sits versus mRNA, gene therapy, and small molecules. Behavioral questions follow a STAR format and consistently probe four themes: scientific judgment under uncertainty, cross-functional collaboration in matrixed teams, comfort with ambiguity as the platform expands into CNS and extra-hepatic tissues, and direct patient-impact motivation grounded in the rare-disease communities Alnylam serves. Compensation conversations are typically reserved for late-stage rounds with the recruiter; do not anchor low, and do not raise comp before the hiring manager has signaled mutual interest. The company prides itself on a 'no jerks' culture and red-flags candidates who treat junior interviewers dismissively, so engage every interviewer in the loop with equal seriousness regardless of title.

What Alnylam Pharmaceuticals Looks For

  • Genuine scientific curiosity about RNA biology and therapeutic modalities — Alnylam's leadership is allergic to mercenary career-stackers and will probe platform conviction directly.
  • Demonstrated ability to ship: FDA approvals, BLA filings, IND-enabling packages, manufacturing scale-ups, or commercial launches with measurable outcomes (revenue, market share, prescriber adoption).
  • Cross-functional collaboration in matrixed environments — Alnylam runs program teams with R&D, clinical, regulatory, CMC, commercial, and medical affairs in tight integration, and interviewers screen for candidates who navigate that without ego.
  • Comfort with ambiguity and platform pivots — siRNA is expanding from liver-targeted GalNAc into CNS, eye, and extra-hepatic tissues, and ideal hires are excited rather than threatened by white-space programs.
  • Patient-focused mission alignment, especially for rare disease roles. Alnylam invests heavily in patient-advocacy partnerships and expects employees to understand the lived experience of ATTR, porphyria, and hyperoxaluria patients.
  • Operational excellence and Boston biotech work ethic — Alnylam is hybrid (typically 3 days on-site for Cambridge roles) and explicitly values teams that ship hard things together in the same room.
  • Diverse perspectives — the company has been recognized on Bloomberg's Gender-Equality Index for multiple consecutive years and has measurable representation goals across leadership.
  • Long-term thinking — RNAi programs run 7-10+ years from target nomination to approval, and Alnylam values candidates whose career arcs reflect the patience to see programs through rather than serial 18-month tour-stops.

Frequently Asked Questions

What ATS does Alnylam use and how should I optimize for it?
Alnylam uses Eightfold AI at jobs.alnylam.com, which combines traditional resume parsing with AI-driven skills inference and cross-references your public LinkedIn profile to score candidate-role fit. Use a single-column ATS-friendly resume in .docx or PDF, mirror exact job-title language from the JD, list skills explicitly (RNAi, siRNA, GalNAc, oligonucleotide synthesis, GMP, ICH guidelines, ICH Q8/Q9/Q10, statistical software, etc.), and ensure your LinkedIn matches your resume so the AI does not flag inconsistencies that drop your match score. Avoid graphics, tables, and text-in-images, which Eightfold's parser still misreads roughly 30% of the time and silently hides your strongest experience.
What is the typical compensation range for entry-level scientists at Alnylam?
Entry-level Cambridge biotech scientist compensation at Alnylam typically runs $115-150K base for Scientist I (PhD, 0-2 years industry) with a 10-15% target bonus and a meaningful RSU grant (often $40-80K vesting over 4 years). Senior Scientist (5-8 years) commonly lands at $160-200K base with 15-20% bonus and larger RSU refreshers. Director-level R&D compensation commonly exceeds $250K base plus 25%+ bonus and significant equity. These numbers track the Cambridge cluster (Vertex, Moderna, Biogen) closely; Alnylam is competitive but not the absolute top of market.
How does Alnylam compensation compare to Vertex, Moderna, and Novartis?
Alnylam base salaries are broadly competitive with Vertex and Moderna and slightly above Novartis Cambridge for equivalent levels. Where Alnylam often loses competitive offers is on RSU grant size at the senior level — Vertex's commercial success and Moderna's COVID-era equity windfalls created a higher equity baseline at peer companies. Alnylam counters with platform-conviction pitch and post-HELIOS-B upside; candidates with strong belief in RNAi often choose Alnylam at modestly lower TC. Field commercial roles are generally on par with Vertex and Moderna and above traditional Big Pharma.
Why do candidates sometimes turn down Alnylam offers?
The most common reasons cited by candidates who decline Alnylam offers: (1) higher RSU grants from Vertex, Moderna, Novartis, or Eli Lilly for equivalent role levels; (2) preference for diversified large-pharma stability over single-platform biotech volatility, especially for candidates near retirement or with risk-averse partners; (3) on-site or hybrid expectations that conflict with fully-remote preferences post-COVID; (4) location lock-in to Cambridge for candidates who don't want to relocate from the West Coast, Triangle area, or Europe; (5) concern about pipeline concentration risk in ATTR/cardiology and intensifying competitive dynamics with Pfizer's tafamidis franchise and BridgeBio's acoramidis launch trajectory.
Does Alnylam sponsor H-1B or TN visas?
Yes, Alnylam routinely sponsors H-1B, TN, O-1, and green card processes for hard-to-fill scientific, clinical, and CMC roles where domestic talent is scarce, and the company has a mature in-house immigration function that handles transfers and conversions efficiently. Sponsorship is more selective for commercial, marketing, and G&A roles where the U.S. talent pool is deeper and the immigration cost-benefit is harder to justify. Disclose visa status candidly during the recruiter screen — Alnylam's TA team can usually give a clear yes/no signal early in the process rather than at offer stage, which protects everyone's time.
What is the on-site expectation at Alnylam?
Most Cambridge-based roles are hybrid with a typical expectation of 3 days per week on-site at the 200 Sidney Street or 675 West Kendall campuses. Bench science, manufacturing, and CMC roles are generally fully on-site. Some commercial field roles (Medical Science Liaisons, field reimbursement, sales) are remote-eligible within assigned territories. Fully remote desk roles are rare and typically reserved for niche specialties (some IT, some specialized regulatory). Confirm specific expectations with the recruiter early — this has shifted post-COVID and varies by function.
How important is RNAi-specific experience versus adjacent modalities?
RNAi-specific experience (siRNA design, GalNAc conjugation, oligonucleotide chemistry, Alnylam-specific platforms) is the single highest-leverage signal for R&D roles and meaningfully helpful for clinical, regulatory, and CMC roles. That said, Alnylam hires heavily from adjacent oligonucleotide therapeutics (Ionis, Sarepta, Stoke), mRNA (Moderna, Pfizer mRNA, BioNTech), gene therapy (BioMarin, Sarepta gene therapy, Spark), and rare-disease commercial organizations (Vertex, Sanofi Genzyme, Ultragenyx, BioMarin). If you are coming from small molecules or biologics without RNA experience, expect tougher technical screens, study Alnylam's published platform papers before the loop, and emphasize transferable platform-development skills.
What is the post-HELIOS-B opportunity and how does it affect hiring?
The HELIOS-B Phase 3 trial showed Amvuttra (vutrisiran) significantly reduced cardiovascular events and all-cause mortality in ATTR cardiomyopathy patients, opening a multibillion-dollar market that competes directly with Pfizer's Vyndaqel/Vyndamax franchise and BridgeBio's acoramidis launch. The label expansion drove a substantial hiring surge in 2024-2025 across cardiovascular medical affairs, field reimbursement, market access, marketing, sales force expansion, commercial analytics, and supporting CMC capacity. Candidates with cardiology launch experience (especially from heart failure, anticoagulants, SGLT2 inhibitors, or PCSK9 launches) are in particularly high demand and can often command premium compensation.
How does Alnylam's interview loop compare to Big Pharma?
Alnylam's loops are typically more compressed than Big Pharma (6-10 weeks for individual contributors versus 3-6 months at Pfizer, Merck, or J&J), more scientifically rigorous in non-bench interviews than typical pharma, and more direct about cultural fit and mission alignment. The company largely avoids the multi-round HR-led behavioral assessments common at large pharma and instead relies on hiring-manager-driven panels with real authority. Decision-making is faster post-loop because Alnylam is still small enough that hiring managers and HR business partners can align quickly without the matrix approval chains that slow Big Pharma offers.
What red flags do interviewers screen for?
Common red flags called out by Alnylam hiring managers: (1) inability to articulate why RNAi specifically (versus 'I want to work in biotech generally'); (2) treating junior interviewers dismissively in panels; (3) over-claiming on resume experience that crumbles under technical probing; (4) lack of patient-impact framing for therapeutic decisions; (5) negative framing of past employers, especially without taking accountability; (6) asking about compensation, equity, or remote work in early rounds before interest is established mutually; (7) inability to engage substantively with the Cambridge biotech ecosystem and Alnylam's specific platform history.

Open Positions

Alnylam Pharmaceuticals currently has 87 open positions.

Check Your Resume Before Applying → View 87 open positions at Alnylam Pharmaceuticals

Related Resources

Similar Companies

Related Articles

Sources

  1. Alnylam Pharmaceuticals Careers —
  2. Alnylam Jobs Portal (Eightfold ATS) —
  3. Alnylam Pharmaceuticals Investor Relations —
  4. Alnylam Pharmaceuticals (Wikipedia) —
  5. Alnylam Leadership and Board —
  6. FDA Approval of Onpattro (patisiran) — 2018 —
  7. HELIOS-B Phase 3 Topline Results (Alnylam Press Release, 2024) —
  8. Eightfold AI Talent Platform —